Two-page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.
Trade negotiators for the Trans-Pacific Partnership agreement in Guam are now focusing on intellectual property issues, which appear likely to be the last hurdle to concluding the talks.
On Monday, a coalition of Peruvian civil society organizations issued a strong warning as negotiations for the Trans Pacific Partnership treaty (TPP) come to an end.
A new report from the prominent AIDS research group amfAR says that the Trans-Pacific Partnership would hamper the global fight against AIDS (and other diseases) in a way that would ultimately cost lives.
A text that Peru and 11 other countries (including the US) are negotiating in secret, seeks to expand drug patents for more than 20 years thus generating millions of overheads for our health system and making it even more difficult to obtain biological medicines against cancer.
Australia’s primary negotiator on medicines for the US-Australia FTA, Dr Ruth Lopert, warns that the TPP could force the Australian Government to spend hundreds of millions of dollars to subsidise medicines.
Chief negotiators in Trans-Pacific Partnership talks failed to iron out differences over the last week, with intellectual property protection on medicines and environmental protection being key stumbling blocks.
The US Ambassador Lippert has sent a letter to the Korean Minister of Food and Drug Safety requesting protection of biologics under the patent linkage system. He also confirmed that the US seeks the same protection in TPP.
TPP — the Trans-PacificPartnership — is making waves from Peru to Australia, concerning public health officials and consumer advocates.
Prof Brook K Baker, Professor of Law and Northeastern University, cautions that the Modi government’s accelerating flirtation with the US and its investors is dangerous to hundreds of millions of people worldwide whose lives depend on Indian generics
Access to affordable medicines could be under threat in Australia if the United States gets its way in secretive negotiations over a massive trade deal involving 12 Pacific-region countries, academics have warned.
Japan is pushing for intellectual property rules in the Regional Comprehensive Economic Partnership that will undermine and delay access to affordable generic medecine in Asia.
Braving snow and blizzard warnings, health, labor and environmental activists rallied outside a New York City hotel on Monday where industry leaders met with international trade representatives to commence the "final negotiations" over the secret text of the Trans-Pacific Partnership.
MSF took its protest against the TPP to the skies, flying an aerial banner that read “Doctors to Obama: Keep #TPP Away From Our Medicines” along the Hudson River.
Only 30% of Vietnam’s eligible HIV patients would have access to ARVs under the US 2014 TPPA proposals, instead of the 68% receiving treatment today.
As the 6th round of negotiations on the Regional Comprehensive Economic Partnership (RCEP) trade agreement take place in India, people living with HIV are rallying in the streets of New Delhi to warn that harmful intellectual property provisions - put forth by Japan - could severely restrict access to affordable medicines for people in developing countries.
The Australian Medical Association (AMA) wants assurances that a Trans Pacific Partnership (TPP) deal will not push up medicine prices.
Australian Trade Minister Andrew Robb lashed out at consumer groups and the Greens for spreading misinformation about the Trans-Pacific Partnership, before walking into a meeting with 11 trade counterparts in Sydney on Saturday to finalise the "basic elements" of the deal.
Many critics are pointing out that the lack of an Ebola vaccine is due to the intellectual property protections offered through trade deals like the Transatlantic Trade and Investment Partnership.
Social organizations defending the interests of health patients have spoken out against the TPP.